The FDA has announced that the administration will expand access to serology tests and its approach to making accurate and reliable serology tests widely available, while also protecting Americans from tests marketed with false or unsubstantiated claims, the FDA announced on Saturday.

The administration will continue to provide developers with a request for FDA authorization through the emergency use authorization (EUA) process. The FDA has already issued four EUAs for serological tests, and expect that number to continue to grow in the coming weeks.

The FDA will encourage developers to submit EUA requests for their tests, as an EUA will provide laboratories and providers with assurance that FDA has reviewed that test. The administration will quickly review EUA submissions and continue to take steps to ensure the process is as streamlined and efficient as possible.

To enhance the U.S. Government’s ability to identify well-performing tests and inform FDA recommendations and decision making, the administration will collaborate with the National Institutes of Health’s National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).

Under the partnerships, the agencies will be able to establish a capability at NIH to evaluate serological tests for developers. The effort will include tests already available for use, as well as tests not yet on the market where additional validation data is needed to support an EUA.

In addition, the FDA has projected performance assessments for serological tests will begin soon, and the administration has expected results shortly thereafter. The administration will review NIH’s results expeditiously, and performance results from NIH’s assessment may complement and inform the determination of whether FDA issues an EUA for a particular test.

About FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Everbridge has announced that the Joint Analytic Real-Time Virtual Information Sharing System (JARVISS) has been deployed to assess and respond to the impact that the COVID-19 outbreak has on Army staff, facilities, installations, and offsite special events, Everbridge reported on Monday.

“At Everbridge, we share a deep sense of appreciation towards those who keep us safe,” said David Meredith, CEO of Everbridge. “We feel honored to power JARVISS and provide the U.S. Army worldwide with the software tools, threat intelligence and data to protect our soldiers and their families from countless threats, including the current COVID-19 pandemic.”

JARVISS, the U.S. Army’s enterprise system for threat visibility, powered by the Everbridge Risk Intelligence Monitoring Center, has primarily focused on antiterrorism and other security threats, including active shooters and natural disasters, that might affect Department of Defense (DoD) operations.

With the outbreak and rapid spread of COVID-19, JARVISS has provided support to ongoing threat analysis of the pandemic, which has given the Army insight into the impact to global DoD operations.

In response to the coronavirus crisis, JARVISS has integrated Everbridge’s new COVID-19 data layers and software for actionable intelligence and report creation. The platform has accessed more than 1,400 situational awareness modules across the globe, as well as data from Everbridge’s Risk Intelligence Monitoring Center feed.

With the technology, Army analysts are able to receive real-time insight into how the virus is disrupting critical infrastructure, including bases in the U.S. and abroad, hospitals, recruiting stations, Reserve and National Guard operational units, police and fire locations.

During the COVID-19 pandemic, JARVISS has provided critical information to State National Guard headquarters as personnel are activated and deployed to support relief efforts across the nation.

JARVISS will continue to provide Army emergency managers, contingency planners, medical, and force protection personnel the data to quickly coordinate with local government, law enforcement, health facilities and other agencies.

In addition, Everbridge has launched a series of actions to address the coronavirus, including providing daily updates on its Coronavirus Preparedness Hub. In response to COVID-19, the Everbridge platform has delivered over 135 million communications specific to coronavirus as well as launched its COVID-19 Shield rapid deployment templates to protect people and maintain operations amid the pandemic.

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running.

During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,000 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans.